We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Riaz
Akhtar
rakhtar@liverpool.ac.uk
Dr
Alena
Shantsila
s.shantsila@liverpool.ac.uk
Provisional assignment of new diseases of uncertain etiology
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
In December 2019, the news of an outbreak of an unusual infection of the lungs (defined as “atypical pneumonia”) raised among media. The infection was associate to a novel respiratory virus (of the coronavirus family – the group of viruses responsible for respiratory infections in humans such as the common cold), and became officially known as severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). The new infection, first appeared in the city of Wuhan in the Hubei province of China and quickly spread around the world, becoming an uncontrolled pandemic and causing the clinical manifestations of the 2019 Coronavirus Disease (COVID-19). Despite the disease being defined as a respiratory infection, the strong impact of COVID-19 on the cardiovascular system has been widely reported.
Current available evidence suggest that COVID-19 leads to negative alterations of the cardiovascular system and accelerates vascular ageing. Additionally, current evidence shows that patients with pre-existing cardiometabolic diseases experience worse outcomes if infected by SARS-Cov-2. To prevent these negative outcomes, it is necessary to gain insight into the long-term vascular consequences of COVID-19 and on the identification of early predictors of cardiovascular events in infected people. For this reason, follow-up studies amongst the survivors of this acute infection are necessary, in order to identify the best approach for a preventive strategy.
The aim of this project is to evaluate whether COVID-19 induces accelerated vascular ageing and whether the speed of vascular ageing is influenced by the severity of the infection and by any pre-existing cardiometabolic disease. An additional aim of this study is to understand if psychosocial factors (e.g., stress following hospitalisation) play a role in the accelerated vascular ageing process induced by COVID-19.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Case-controlled study;
You can take part if:
You may not be able to take part if:
- Aged under 18 years. - Aged over 80 years. - Inability to express consent for this study. - Pregnancy or breastfeeding. - Congenital defects or anomalies. - Diseases carrying out a life expectancy of < 1 year according to clinical judgement. - Foreseen inability to attend scheduled visits.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Liverpool and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 51512
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
